Cannabinoid Encyclopedia

How cannabinoids work

What is NAPE-PLD?

A simple explanation of NAPE-PLD, why cannabinoid researchers study it, and what its biology can and cannot tell us.

Updated July 2026 19 research sources Human and early research

The short answer

Where NAPE-PLD fits into cannabinoid biology

NAPE-PLD is a biological target studied to understand how cannabinoids affect cells and signaling. Research on THC, CBG, CBN, and CBC helps explain possible mechanisms. This page brings together 7 human-study sources, 8 research reviews, and 4 lab, animal, or mechanism sources. The source set includes human research as well as earlier-stage studies. A mechanism alone does not prove that a cannabinoid will produce a health benefit in people. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about NAPE-PLD.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on NAPE-PLD covers THC, CBG, and CBN; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about NAPE-PLD

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human research included

THC

Studies examine how THC connects with NAPE-PLD or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 2

Mostly mechanism-focused

CBG

Studies examine how CBG connects with NAPE-PLD or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 3

Mostly mechanism-focused

CBN

Studies examine how CBN connects with NAPE-PLD or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 4

Mostly mechanism-focused

CBC

Studies examine how CBC connects with NAPE-PLD or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 3

Human and early-stage research

Endocannabinoids

Studies examine how Endocannabinoids connects with NAPE-PLD or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 5

Mostly preclinical

CBDV

Studies examine how CBDV connects with NAPE-PLD or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 6

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

7 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

8 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

4 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on NAPE-PLD is not one kind of study. This source set includes 8 narrative or expert reviews, 5 animal studies, 3 cell or laboratory studies, and 1 clinical study in people. 3

The recorded populations or models include people or patients (8 sources), animal models (3 sources), and cells or tissue models (3 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is endocannabinoid enzyme activity or metabolic mechanisms (16 sources), receptor, target, metabolic, or pharmacology mechanisms (1 source), and receptor, transporter, target, metabolic, or pharmacology mechanisms (1 source). Closely related outcome names can still describe different measurements. 5

The NAPE-PLD source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

animal study

Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice.

On this page, this source examines Endocannabinoids activity involving endocannabinoid enzyme activity or metabolic mechanisms. 1

Study type
animal study
Population or model
animal models
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
mechanism-focused research

narrative or expert review

FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.

On this page, this source examines THC activity involving endocannabinoid enzyme activity or metabolic mechanisms. 2

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

cell or laboratory study

Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation.

On this page, this source examines CBG activity involving receptor, target, metabolic, or pharmacology mechanisms and CBC activity involving receptor, transporter, target, metabolic, or pharmacology mechanisms. 3

Study type
cell or laboratory study
Population or model
cells or tissue models
Outcome focus
receptor, target, metabolic, or pharmacology mechanisms and receptor, transporter, target, metabolic, or pharmacology mechanisms
Evidence stage
mechanism-focused research

cell or laboratory study

Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes.

On this page, this source examines CBN and skin and inflammatory dermatology. 4

Study type
cell or laboratory study
Population or model
people or patients
Outcome focus
skin, dermatology, inflammatory, or immune-modulation outcomes
Evidence stage
mechanism-focused research

narrative or expert review

Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.

On this page, this source examines Endocannabinoids activity involving endocannabinoid enzyme activity or metabolic mechanisms. 5

Study type
narrative or expert review
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on NAPE-PLD should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What does NAPE-PLD do?

NAPE-PLD is studied as part of cannabinoid-related biology and signaling. The exact role depends on the tissue, compound, and experimental setting. 7

Does a biological mechanism prove a health effect?

No. A mechanism can explain why an idea is plausible, but human studies are needed to test whether it changes a health outcome. 8

What research is linked to NAPE-PLD?

The main areas on this page include THC, CBG, CBN, and CBC. The source links show the study type behind each area. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice. animal study; mechanism-focused research PubMed 41092478 DOI 10.1093/ejendo/lvaf212
  2. 2
    FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. narrative or expert review; evidence still limited PubMed 20047159
  3. 3
    Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation. cell or laboratory study; mechanism-focused research PubMed 40706771 DOI 10.1016/j.reprotox.2025.109006
  4. 4
    Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. cell or laboratory study; mechanism-focused research PubMed 39275884 DOI 10.1002/biof.2122
  5. 5
    Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. narrative or expert review; evidence still limited PubMed 32203086 DOI 10.1038/s41401-020-0385-7
  6. 6
    Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. clinical study in people; preclinical research PubMed 34179865 DOI 10.1016/j.ibneur.2021.01.004
  7. 7
    Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). human research PubMed 22969151 DOI 10.1194/jlr.m030411
  8. 8
    Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta. human research PubMed 32829065 DOI 10.1016/j.bbalip.2020.158807
  9. 9
    Chemical Probes for Investigating the Endocannabinoid System. narrative or expert review; evidence still limited PubMed 39747798 DOI 10.1007/7854_2024_563
  10. 10
    Critical enzymes involved in endocannabinoid metabolism. narrative or expert review; evidence still limited PubMed 17346227 DOI 10.2174/092986607780090829
  11. 11
    Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. narrative or expert review; evidence still limited PubMed 34959715 DOI 10.3390/ph14121316
  12. 12
    Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease. narrative or expert review; evidence still limited PubMed 30564946 DOI 10.1007/s00726-018-2682-8
See all 19 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. clinical study in people; preclinical research / 1 linked research note PubMed 34179865
  2. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. narrative or expert review; evidence still limited / 1 linked research note PubMed 32203086
  3. Inhibition of endocannabinoid hydrolases MAGL, FAAH and ABHD6 by AKU-005 reduces ex vivo cortical spreading depression. animal study; mechanism-focused research / 1 linked research note PubMed 40269679
  4. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease? narrative or expert review; evidence still limited / 1 linked research note PubMed 34217798
  5. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. narrative or expert review; evidence still limited / 1 linked research note PubMed 20047159
  6. Potential of Fatty Acid Amide Hydrolase (FAAH), Monoacylglycerol Lipase (MAGL), and Diacylglycerol Lipase (DAGL) Enzymes as Targets for Obesity Treatment: A Narrative Review. narrative or expert review; evidence still limited / 1 linked research note PubMed 34959715
  7. Inhibition of endocannabinoid synthesis enzymes DAGL and NAPE-PLD transiently lowers body weight and alters glucose homeostasis during a high-fat diet challenge in mice. animal study; mechanism-focused research / 1 linked research note PubMed 41092478
  8. Subcellular localization of NAPE-PLD and DAGL-α in the ventromedial nucleus of the hypothalamus by a preembedding immunogold method. animal study; preclinical research / 1 linked research note PubMed 24346263
  9. Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression. animal study; mechanism-focused research / 1 linked research note PubMed 39245706
  10. Critical enzymes involved in endocannabinoid metabolism. narrative or expert review; evidence still limited / 1 linked research note PubMed 17346227
  11. Chemical Probes for Investigating the Endocannabinoid System. narrative or expert review; evidence still limited / 1 linked research note PubMed 39747798
  12. Structural properties and role of the endocannabinoid lipases ABHD6 and ABHD12 in lipid signalling and disease. narrative or expert review; evidence still limited / 1 linked research note PubMed 30564946
  13. Impact of tetrahydrocannabinol on the endocannabinoid 2-arachidonoylglycerol metabolism: ABHD6 and ABHD12 as novel players in human placenta. human research / 1 linked research note PubMed 32829065
  14. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. narrative or expert review; evidence still limited / 1 linked research note PubMed 21418147
  15. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. animal study; preclinical research / 1 linked research note PubMed 30075103
  16. Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). human research / 1 linked research note PubMed 22969151
  17. Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39275884
  18. Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation. cell or laboratory study; mechanism-focused research / 2 linked research notes PubMed 40706771
  19. Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 35628241